Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp (NASDAQ: WGS) drives innovation in genomic medicine through advanced sequencing technologies and clinical decision support tools. This news hub provides investors and healthcare professionals with essential updates on the company's progress in transforming rare disease diagnosis and precision medicine.
Access authoritative reports covering earnings announcements, research collaborations, regulatory milestones, and technology advancements. Our curated collection includes press releases about clinical study validations, healthcare system partnerships, and innovations in rapid whole genome sequencing applications.
Stay informed about developments in pediatric genetics, oncology diagnostics, and data integration initiatives that demonstrate GeneDx's leadership in translating genomic insights into actionable health solutions. Regular updates ensure you never miss critical information about diagnostic capabilities expansion or strategic growth in the genomic testing market.
Bookmark this page for direct access to verified updates and analysis-free reporting on WGS's role in advancing evidence-based genetic medicine. Check back frequently to monitor how GeneDx continues to shape the future of personalized healthcare through cutting-edge science and clinical partnerships.
GeneDx (Nasdaq: WGS) has announced a new patient access program to increase accessibility to exome sequencing for pediatric epilepsy patients. The program, developed with biopharma partners, aims to provide equitable care and overcome cost barriers for genetic testing. Exome testing, recommended as a first-line test by the National Society of Genetic Counselors and endorsed by the American Epilepsy Society, offers a nearly 25% diagnostic rate for epilepsy, higher than traditional multi-gene panels. Research indicates that genetic diagnoses can lead to up to 90% seizure reduction in some cases. The program will launch to select providers today, with full availability in July.
GeneDx (Nasdaq: WGS) announced its participation in two upcoming investor conferences in June 2024. The company will present at the Jefferies Healthcare Conference in New York City on June 5 at 9:00 a.m. ET and at the 44th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on June 10 at 3:20 p.m. ET. Live and archived webcasts of the presentations will be accessible on the GeneDx investor relations website. GeneDx focuses on delivering improved health outcomes through genomic insights and offers exome and genome tests to provide personalized health plans, accelerate drug discovery, and enhance health system efficiencies.
GeneDx Holdings Corp. (Nasdaq: WGS) reported first quarter 2024 revenue of $61.5M with 96% year-over-year growth in exome and genome test revenue. Expanded adjusted gross margins to 61%, narrowed adjusted net loss to $8.5M, and raised guidance to $235-$245M for FY 2024 revenue. GeneDx aims for profitability in 2025, showcasing a strong performance and strategic initiatives.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
